Potential of longitudinal data from single site and multi-center clinical trials for AI-research

Prof. Dr. Hans-Christoph Becker from Stanford University, a long-standing user of mint Lesion™, shares his experience of using the software in this brief interview. He talks about the reaction he received when sharing the mint report for the first time, how patients benefit from the longitudinal overview of disease, and his plans to use the structured data for AI research.

Related Resources

Related Resources

RECIST measurements of a patient with uveal melanoma and hepatic metastases

University Hospital Tuebingen: Study compares the Efficacy of SIRT and CS-PHP in Uveal Melanoma with Hepatic Metastasis

A study[1] conducted by researchers at University Hospital Tuebingen retrospectively compared the efficacy of two liver-targeted therapies,…

Study Analyzing the Tumor Growth Rate as a Prognostic Biomarker in Lymphoma Patients Under CAR T-Cell Therapy

University Hospital Munich (LMU): Study Analyzing the Tumor Growth Rate as a Prognostic Biomarker in Lymphoma Patients Under CAR T-Cell Therapy

A recent study[1] conducted by researchers at the University Hospital Munich (LMU) investigated the role of tumor growth rate (TGR) in predicting the…

A picture of a person looking at a brain scan and the interface of mint Lesion™  on a computer

Advancing Neuro-Oncology Assessments: Mint Medical to Integrate Newly Published RANO 2.0 Criteria into mint Lesion™

Glioblastomas and other gliomas are the most common malignant primary brain tumor types, yet few effective therapies are available. Clinical research…